Clincosm LogoSign in Get a demo

Food Effect Study of D-0502 Tablet in Healthy Volunteers

Sponsor
InventisBio Co., Ltd (Industry)
Overall Status
Completed
CT.gov ID
NCT03810625
Collaborator
(none)
14
Enrollment
1
Location
2
Arms
5.8
Actual Duration (Months)
2.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is an open label, randomized, balanced, single dose, two-treatment (fed vs. fasting), two-period, two-sequence crossover study of postmenopausal female healthy subjects.

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
14 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase I, Randomized, Open Label, Two-Sequence, Two-Period Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of D-0502 Tablet in Postmenopausal Female Healthy Subjects
Actual Study Start Date :
Oct 23, 2018
Actual Primary Completion Date :
Nov 21, 2018
Actual Study Completion Date :
Apr 17, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Sequence AB

D-0502 Dose Patients will get D-0502 single agent once in the fasted state and once in the fed state.

Drug: D-0502
D-0502 oral tablets
Experimental: Sequence BA

D-0502 Dose Patients will get D-0502 single agent once in the fed state and once in the fasted state.

Drug: D-0502
D-0502 oral tablets

Outcome Measures

Primary Outcome Measures

  1. Pharmacokinetic: area under the plasma concentration versus time curve (AUC) [Day 1 through 4, Day 7 through 11]

    AUC: area under the plasma concentration versus time curve for D-0502; Unit: nM*hr

  2. Pharmacokinetic: maximum plasma drug concentration (Cmax) [Day 1 through 4, Day 7 through 11]

    Cmax: maximum plasma drug concentration of D-0502; Unit: nM

  3. Pharmacokinetic: Time to reach the Cmax (Tmax) [Day 1 through 4, Day 7 through 11]

    Tmax: Time to reach the Cmax of D-0502; Unit: hr

  4. Pharmacokinetic: Apparent terminal half-life (t1/2) [Day 1 through 4, Day 7 through 11]

    t1/2: apparent terminal half-life of D-0502; Unit: hr

Secondary Outcome Measures

  1. Incidence of Treatment-Emergent Adverse Events [2 weeks]

    Number of treatment-related adverse events as assessed by CTCAE v4.0

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  1. Subjects must be medically documented as healthy and acceptable at physical examination.

  2. Subjects must have a BMI between 18.0 and 32.0 kg/m2 and a body weight of 45 kg or higher.

  3. Subjects must have all laboratory parameters within the normal range or considered not clinically significant by the principal investigator.

  4. Subjects must have a normal urinalysis, eGFR, ECG or results considered not clinically significant by the principal investigator.

  5. Subjects must be female with postmenopausal status defined as meeting at least one of the following criteria:

  6. Have undergone a bilateral oophorectomy any time in life;

  7. Age ≥60 years, or

  8. Age <60 years but have cessation of regular menses ≥12 months with follicle stimulating hormone (FSH) value >40 milli-international units per milliliter (mIU/mL) and an estradiol value <40 picograms per milliliter (pg/mL) (140 picomoles per liter [pmol/L]).

  9. Subjects are able to understand the study procedures and risks involved and must provide signed informed consent to participate in the study.

Exclusion Criteria:

  1. Subjects with any history or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological or psychiatric disorders, as determined by the investigator.

  2. Subjects who have any history or suspicion of kidney stones.

  3. Subjects who are positive for human immunodeficiency virus (HIV), Hepatitis B, and/or Hepatitis C.

  4. Subjects who have used prescription drugs, over-the-counter drugs, or natural health products (including herbal remedies, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 14 days before Day 1 of study medication dosing.

  5. Subjects had undergone major surgery within 3 months prior to Day 1.

  6. Subjects who is participating in a clinical research study involving the administration of an investigational or marketed drug or device, or who received any investigational test article within 5 half-lives or 30 days prior to Day 1 study medication dosing.

  7. Subjects with positive urine drug screen test at screening.

  8. Subjects with any condition that, in the judgment of the investigator, would place him/her at undue risk, or potentially compromise the results or interpretation of the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Covance Daytona Beach Clinical Research Unit Daytona Beach Florida United States 32117

Sponsors and Collaborators

  • InventisBio Co., Ltd

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
InventisBio Co., Ltd
ClinicalTrials.gov Identifier:
NCT03810625
Other Study ID Numbers:
  • IBIO-302
First Posted:
Jan 18, 2019
Last Update Posted:
Aug 7, 2019
Last Verified:
Aug 1, 2019
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Aug 7, 2019